TG Therapeutics, Inc. · TGTX · Next earnings

TG Therapeutics, Inc. reports Thursday, Feb 25, 2027

TGTX reports before market open with consensus EPS at $0.52 and revenue at $290.2M. Last quarter: TG Therapeutics raises 2026 revenue outlook as BRIUMVI momentum continues

Reports Before market open95 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $0.52 Calendar consensus
Consensus revenue $290.2M Calendar consensus
Report date Feb 25, 2027 Thursday, date estimated
Session Before market open 95 days away

Where TGTX left off: FY2026 Q3

Full report

TG Therapeutics raises 2026 revenue outlook as BRIUMVI momentum continues

EPS surprise -2.6% Reported $0.35 vs $0.36
Revenue surprise +5.9% Reported $259.9M vs $245.5M
Stock move +5.9% Event window
Subsequent drift +3.8% Up to 20 sessions
Check the math in the surprise calculator >

Raised: global full-year revenue guidance is now $1 billion, and U.S. BRIUMVI net revenue guidance is $915–$920 million. The prior-quarter analysis recorded global guidance of approximately $950 million and U.S. guidance of $890–$905 million.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Payer access and gross-to-net discounts could pressure revenue or margins.
  • Competition from existing anti-CD20 therapies and potential BTK inhibitor entrants may affect adoption.
  • Regulatory, manufacturing and CMC execution could delay planned formulations or launches.
  • The clinical and commercial potential of pipeline programs remains uncertain.
  • Potential changes to 340B policy could affect a portion of the business.

Questions analysts left open

  • Sustainability of gross-to-net discounts and payer access.
  • Potential market impact of upcoming BTK inhibitor agents.
  • Timing and commercial impact of the simplified IV dosing regimen.
  • Uptake speed and pricing dynamics for subcutaneous BRIUMVI.
  • Extent of 340B policy changes on revenue.

Ask FN2 about TGTX next report

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Get the TGTX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent TGTX quarters

All TGTX earnings

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.